Hero image

Research & products

We run to, not from, the world’s biggest health challenges.

The journey to invention and discovery is guided by science – and inspired by patients

Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.

Our work in numbers

16.7K

people employed in research and development

422M

people reached through our major programs and partnerships

$13.6B

invested in R&D in 2020

We address the world’s most difficult health challenges, following world-class science

Hero_RGB_Discovery-Blue
Discovery & development

Step inside Merck Research Laboratories (MRL) where our quest to save and improve lives through research and development begins

B5 - Our pipeline__
Pipeline

We’re focused on inventing new medicines and vaccines to help more people

B5 we work to deliver
Products

Our focus on breakthrough science is working

Clinical trials

Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.

Father playing with young son at breakfast table

Our commitment to patients is unwavering

As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.

Invention begins here

Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccines

View our stories

Our fourth-quarter and full-year 2020 financial results

Merck announced fourth-quarter worldwide sales of $12.5 billion – an increase of 5%, and full-year 2020 worldwide sales of $48.0 billion – an increase of 2%. Excluding the impact from foreign exchange, sales grew 4%. The company anticipates full-year 2021 worldwide sales to be between $51.8 billion and $53.8 billion, including a positive impact from […]

See earnings

Next: Our fourth-quarter and full-year 2020 financial results

No matter rain, nor snow…

In the face of increasing global demand for one of our cancer medicines, our manufacturing teams in Durham, North Carolina, have gone above and beyond. When the other suppliers stopped production, Merck responded by stretching the production processes and enabling production to the full extent of our manufacturing equipment capacity. The Durham team increased production […]

Read more

Next: No matter rain, nor snow…

When work hits close to home

For Chris Hinson, one of our colleagues, Merck’s commitment to making our medicines available to patients is very personal

Read more

Next: When work hits close to home

When patients are in need, we answer the call

Merck’s Board of Directors approves expansion of our plant in Durham, North Carolina, to help patients

Read more

Next: When patients are in need, we answer the call

Confronting a new era in immunization

By John Markels, Ph.D., president, Merck Vaccines

Read more

Next: Confronting a new era in immunization

Previous
Next